证券代码：688739 证券简称：成大生物 辽宁成大生物股份有限公司 投资者关系活动记录表 编号：2022-005 | --- | --- | --- | --- | --- | |-------------------------|--------------------------------|---------------------------------------------------------------------------------------------------------------------------|----------------------------------|------------------| | | | | | | | | | | | | | | | □特定对象调研 □分析师会议 □媒体采访 □业绩说明会 | | | | 投资者关系活 | □新闻发布会 □路演活动 | | □现场参观 □电话会议 | | | 动类别 | | ■网络会议 □其他（请文字说明其他活动内容） | | | | 参与单位名称 及人员姓名 | | 华泰证券、国盛证券、平安养老、兴业 ...

Revenue and Profit - Q3 2022 revenue was CNY 478,932,803.95, a decrease of 14.86% year-over-year, while year-to-date revenue reached CNY 1,360,237,730.36, down 21.60% compared to the same period last year[5] - Net profit attributable to shareholders for Q3 2022 was CNY 208,089,828.05, a decline of 17.80% year-over-year, with year-to-date net profit at CNY 589,155,273.08, down 28.90%[5] - The net profit after deducting non-recurring gains and losses for Q3 2022 was CNY 193,658,152.11, a decrease of 29.32% year-over-year, and year-to-date it was CNY 527,672,899.23, down 36.56%[5] - Basic earnings per share for Q3 2022 was CNY 0.50, a decrease of 26.47%, while year-to-date basic earnings per share was CNY 1.41, down 36.20%[9] - Total operating revenue for the first three quarters of 2022 was CNY 1,360,237,730.36, a decrease of 21.6% compared to CNY 1,734,997,459.03 in the same period of 2021[30] - Net profit for the third quarter of 2022 was CNY 589,155,273.08, down 29.0% from CNY 828,635,843.67 in the third quarter of 2021[33] - The net profit for the first three quarters of 2022 was approximately CNY 660.63 million, down 21.4% from CNY 840.88 million in the same period of 2021[51] - The total profit for the first three quarters of 2022 was approximately CNY 765.03 million, down 21.1% from CNY 969.90 million in the same period of 2021[51] Cash Flow and Assets - Cash flow from operating activities for the year-to-date period was CNY 310,572,683.78, reflecting a 32.80% increase[9] - As of September 30, 2022, the company's cash and cash equivalents amounted to RMB 4,287,237,727.90, an increase from RMB 2,829,271,603.08 as of December 31, 2021, reflecting a growth of approximately 51.5%[21] - The company's cash inflow from operating activities totaled CNY 1,234,848,778.43, compared to CNY 1,124,479,817.39 in the same period last year[38] - The net cash flow from operating activities for the first three quarters of 2022 was approximately CNY 356.80 million, an increase of 48.8% compared to CNY 239.84 million in the same period of 2021[56] - The net cash flow from investing activities for the first three quarters of 2022 was approximately CNY 1.49 billion, compared to a negative cash flow of CNY 877.94 million in the same period of 2021[56] - Cash and cash equivalents at the end of the period reached CNY 4,250,987,476.02, compared to CNY 347,775,570.81 at the same time last year[41] Research and Development - R&D investment totaled CNY 67,683,330.42 in Q3 2022, accounting for 14.13% of revenue, an increase of 2.01 percentage points year-over-year[9] - Research and development expenses for the first three quarters of 2022 were CNY 162,544,758.79, a slight decrease from CNY 171,514,747.15 in the previous year[30] - The company's research and development expenses for the first three quarters of 2022 were approximately CNY 143.44 million, a decrease of 11.8% compared to CNY 162.63 million in the same period of 2021[51] Assets and Liabilities - Total assets at the end of Q3 2022 were CNY 9,928,282,704.56, an increase of 1.38% from the end of the previous year[9] - The total current assets decreased to RMB 7,639,663,115.05 from RMB 7,797,521,798.66, indicating a decline of about 2.03%[25] - The company's total assets reached RMB 9,928,282,704.56, up from RMB 9,792,731,456.06, representing an increase of approximately 1.38%[25] - The total liabilities decreased to RMB 403,561,883.39 from RMB 440,715,907.97, showing a reduction of about 8.43%[28] - The company's accounts receivable increased to RMB 1,150,408,046.94 from RMB 958,173,371.60, marking a rise of approximately 20.05%[25] - The inventory value rose to RMB 479,723,398.11 from RMB 385,155,199.04, reflecting an increase of about 24.6%[25] - The non-current assets totaled RMB 2,288,619,589.51, up from RMB 1,995,209,657.40, indicating a growth of approximately 14.7%[25] - The company's total equity attributable to shareholders reached CNY 9,524,720,821.17, an increase from CNY 9,352,015,548.09 year-over-year[30] - The total liabilities decreased to CNY 259,439,005.53 from CNY 421,212,228.65 year-over-year[46] Financial Performance and Expenses - Total operating costs decreased to CNY 718,731,679.43 from CNY 752,265,911.84, reflecting a reduction of 4.5%[30] - The company reported a decrease in employee compensation payable from RMB 110,597,075.62 to RMB 72,287,501.59, a decline of about 34.6%[28] - The company reported a decrease in sales expenses to approximately CNY 267.52 million in 2022 from CNY 249.58 million in 2021, reflecting a 7.2% increase[51] - The company’s tax expenses for the first three quarters of 2022 were approximately CNY 104.40 million, a decrease of 19.1% compared to CNY 129.02 million in the same period of 2021[51] - The company’s financial income showed a significant increase, with interest income rising to approximately CNY 36.26 million from CNY 3.77 million in the previous year[51] Company Strategy and Market Conditions - The company reported a decrease in net profit due to the ongoing impact of the COVID-19 pandemic and market competition, but noted that the decline in revenue and profit has narrowed compared to earlier reports in the year[12] - The company has implemented measures to improve sales and manage accounts receivable, contributing to the increase in cash flow from operating activities[12] - The company has not disclosed any significant new product developments or market expansion strategies during the reporting period[20]

Financial Performance - The company reported a total revenue of RMB 500 million for the first half of 2022, representing a year-on-year increase of 15%[1]. - The net profit attributable to shareholders was RMB 100 million, with a growth rate of 20% compared to the same period last year[1]. - The company's operating revenue for the first half of 2022 was CNY 881,304,926.41, a decrease of 24.83% compared to CNY 1,172,443,007.72 in the same period last year[26]. - Net profit attributable to shareholders for the first half of 2022 was CNY 381,065,445.03, down 33.78% from CNY 575,486,681.86 year-on-year[26]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was 334.01 million yuan, a decline of 40.11% year-on-year[104]. - The company achieved operating revenue of 881.30 million yuan, a year-on-year decrease of 24.83%[104]. - The net profit attributable to the parent company was 381.07 million yuan, down 33.78% year-on-year[104]. - Operating cash flow increased by 62.90% to 172.71 million yuan[66]. Research and Development - The company is investing RMB 50 million in R&D for innovative vaccine technologies, focusing on enhancing efficacy and safety[1]. - The R&D investment as a percentage of operating revenue increased to 17.16%, up 4.41 percentage points from 12.75% in the previous year[26]. - The total R&D investment amounted to approximately ¥151.25 million, representing a year-on-year increase of 1.18%[52]. - The company has established three major R&D technology platforms for bacterial vaccines, viral vaccines, and multi-valent vaccines, with over 20 vaccine varieties under development[34]. - The company is currently conducting 14 research projects, with the most significant being the 15-valent HPV vaccine, which has a total expected investment of ¥100,000,000 and is in the process of obtaining clinical trial approval[55]. - The company has established a VLP technology platform that enhances the immunogenicity and safety of vaccines, particularly for HPV and hepatitis B vaccines[46]. - The company’s R&D expenses increased by 2.53% compared to the previous year, with a total of ¥114.92 million in expensed R&D[52]. Market Strategy and Expansion - Future outlook includes an expected revenue growth of 30% for the second half of 2022, driven by new product launches and market expansion[1]. - Market expansion strategies include entering Southeast Asian markets, targeting a revenue contribution of 5% from these regions by 2023[1]. - The company plans to launch two new vaccine products by the end of 2022, aiming to capture a 10% market share in the new segments[1]. - The company is focusing on innovative immunization schedules, such as the Zagreb 2-1-1 regimen for rabies vaccination, which reduces the number of visits and doses required[60]. Risk Management - Risk factors identified include regulatory changes and competition, with mitigation strategies outlined in the report[1]. - The company is facing risks due to a relatively single product structure, primarily relying on human rabies and inactivated Japanese encephalitis vaccines for revenue and profit[82]. - The company is actively managing accounts receivable risks by enforcing a strict customer admission system and credit evaluation process to mitigate potential losses from defaults[88]. - The company is closely monitoring macroeconomic conditions to mitigate investment risks and ensure compliance with investment regulations[92]. Environmental and Compliance - The company has established a comprehensive environmental management system and obtained GB/T 24001-2016/ISO14001:2015 certification[144]. - The company has implemented a wastewater treatment system that meets discharge standards, with regular monitoring of pollutants[133]. - The company is classified as a key pollutant discharge unit and adheres to environmental regulations, ensuring all emissions meet national standards[132]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[140]. Corporate Governance and Shareholder Relations - The company has established a profit distribution policy prioritizing cash dividends, with a minimum cash distribution of 10% of the annual distributable profit if there are no major investment plans[176]. - The company commits to a gradual reduction of shares post-lockup period, adhering to relevant regulations and ensuring the reduction price is not lower than the IPO price[169]. - The company will ensure that any related party transactions are conducted at fair market prices and will disclose necessary information as required by regulations[187]. - The company has outlined specific conditions under which the lock-up period may be extended[156].

Financial Performance - The company's revenue for Q1 2022 was ¥366,344,805.12, representing a decrease of 38.46% compared to the same period last year[5] - Net profit attributable to shareholders was ¥150,924,190.74, down 46.16% year-over-year[5] - The net profit after deducting non-recurring gains and losses was ¥132,845,531.04, reflecting a decline of 53.21% compared to the previous year[5] - Basic earnings per share decreased by 52.00% to ¥0.36[5] - Total operating revenue for Q1 2022 was ¥366,344,805.12, a decrease of 38.5% compared to ¥595,277,477.18 in Q1 2021[38] - Net profit for Q1 2022 was ¥150,924,190.74, a decline of 46.3% from ¥280,299,418.02 in Q1 2021[40] - Basic and diluted earnings per share for Q1 2022 were both ¥0.36, compared to ¥0.75 in Q1 2021[41] - The net profit for Q1 2022 was ¥178,776,652.90, down 37.4% from ¥285,751,337.31 in Q1 2021[56] Research and Development - R&D investment totaled ¥69,235,416.34, a decrease of 16.42%, but accounted for 18.90% of revenue, an increase of 4.98 percentage points[7] - The company has initiated the construction of a biotechnology product R&D and production base with an estimated investment of RMB 1.4 billion to support the production needs of its HPV vaccine and other products[25] - The company is actively developing its ACYW135 meningococcal polysaccharide conjugate vaccine, with clinical trial applications accepted in March 2022[23] - Research and development expenses for Q1 2022 were ¥47,298,376.40, down 26.4% from ¥64,259,108.26 in Q1 2021[38] - Research and development expenses for Q1 2022 were ¥29,011,936.92, down 51.5% from ¥59,789,820.21 in Q1 2021[56] Cash Flow and Liquidity - The net cash flow from operating activities was ¥38,146,275.72, with an increase in cash received from sales compared to the previous year[13] - In Q1 2022, the company reported a net cash flow from operating activities of ¥38,146,275.72, a significant improvement compared to a net outflow of ¥27,054,458.17 in Q1 2021[43] - The company's cash inflow from operating activities totaled ¥320,536,823.33 in Q1 2022, an increase of 22.2% from ¥262,351,166.86 in Q1 2021[60] - Cash and cash equivalents at the end of Q1 2022 amounted to ¥2,270,823,998.45, down from ¥365,354,543.10 at the end of Q1 2021[45] - The net cash flow from investment activities was negative at ¥540,349,528.56, slightly better than the negative ¥593,850,177.17 recorded in Q1 2021[45] - Cash flow from financing activities resulted in a net outflow of -365,495.58, compared to -354,850.08 in the previous period[63] - The net increase in cash and cash equivalents for the period was -510,753,753.85, showing a decrease in liquidity[63] Assets and Liabilities - Total assets at the end of the reporting period were ¥9,889,979,317.86, a slight increase of 0.99% from the end of the previous year[7] - The company's total assets increased to RMB 9,889,979,317.86 as of March 31, 2022, compared to RMB 9,792,731,456.06 as of December 31, 2021, reflecting a growth of about 1.0%[30] - The company's inventory as of March 31, 2022, was RMB 413,638,378.11, up from RMB 385,155,199.04 as of December 31, 2021, indicating an increase of approximately 7.0%[30] - Total liabilities decreased to ¥387,039,579.03 in the latest report from ¥440,715,907.97 in the previous period[33] - The company's total liabilities decreased to ¥249,198,833.13 in Q1 2022 from ¥421,212,228.65 in Q1 2021, representing a reduction of 40.8%[56] - The company's total equity increased to ¥9,602,030,411.99 in Q1 2022 from ¥9,423,253,759.09 in Q1 2021, reflecting a growth of 1.9%[56] Market Conditions - The decline in revenue was attributed to the impact of the Omicron variant and tightened domestic pandemic control measures, leading to reduced market demand[12] - The company faced increased competition in the human rabies vaccine market, contributing to the revenue decline[12] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 31,021[15] - Four of the top ten shareholders are involved in margin trading, holding a total of 73.43 million shares through credit securities accounts[20]

Financial Performance - The company achieved a net profit attributable to shareholders of the parent company of ¥892,490,658.44 in 2021, with a total profit available for distribution to shareholders of ¥892,229,814.14 after statutory surplus reserve allocation[8]. - A cash dividend of ¥10 per 10 shares (including tax) is proposed, totaling ¥416,450,000, which accounts for 46.66% of the net profit attributable to shareholders of the parent company for 2021[8]. - The company reported a total revenue of RMB 1.2 billion for the fiscal year 2021, representing a year-over-year growth of 15%[26]. - The company achieved operating revenue of CNY 2,088,043,469.78 in 2021, representing a year-on-year increase of 4.63%[33]. - The net profit attributable to shareholders was CNY 892,490,658.44, a decrease of 2.80% compared to the previous year[37]. - The net profit after deducting non-recurring gains and losses was CNY 862,518,502.00, reflecting a year-on-year increase of 2.13%[37]. - The net cash flow from operating activities was CNY 506,376,172.18, down 41.09% year-on-year, primarily due to delayed customer payments caused by the COVID-19 pandemic[37]. - The company's total assets reached CNY 9,792,731,456.06 at the end of 2021, an increase of 118.67% compared to the end of 2020[38]. - The net assets attributable to shareholders increased to CNY 9,352,015,548.09, marking a growth of 127.09% year-on-year[38]. - Basic earnings per share decreased by 4.49% to CNY 2.34 in 2021[36]. Research and Development - The R&D expenditure accounted for 14.91% of operating revenue, an increase of 3.77 percentage points compared to the previous year[36]. - The company has established three major R&D technology platforms, with over 20 vaccine varieties currently under research, including innovative and multi-valent vaccines[66]. - The company’s total R&D investment for the year reached ¥311,399,620.91, representing a year-on-year increase of 40.04% and accounting for 14.91% of the company's operating revenue[112][113]. - The company filed 17 new intellectual property applications during the reporting period, including 9 invention patent applications, and received 3 patent grants[111]. - The number of R&D personnel increased to 170, up from 155 in the previous year, with R&D personnel accounting for 11.12% of the total workforce[121]. - The company is currently conducting clinical trials for several vaccines, including the quadrivalent influenza vaccine, which is in Phase III trials with a total investment of ¥29,800,000[117]. - The company is actively expanding its R&D efforts, with a focus on new product development and clinical trials for various vaccines[113][117]. - The company has established three distinct technology platforms for vaccine development: bacterial vaccines, viral vaccines, and multi-valent vaccines, aligning with industry trends[102]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 25% market share by 2025[26]. - The company has completed the acquisition of a local biotech firm, which is expected to enhance its R&D capabilities and product pipeline[26]. - The company is enhancing its management system post-listing, focusing on risk prevention and talent recruitment to support future development[62]. - The company is committed to increasing R&D investment to mitigate long-term technology iteration risks and ensure the leading position of its core technology[129]. - The company is focusing on expanding its product portfolio to reduce risks associated with a relatively single product structure, particularly in rabies and encephalitis vaccines[135]. Operational Challenges and Risks - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[12]. - The company has not violated decision-making procedures for external guarantees[12]. - The company has not faced any issues with more than half of the directors being unable to ensure the authenticity, accuracy, and completeness of the annual report[12]. - The company is closely monitoring macroeconomic conditions to manage investment risks effectively[145]. - The company faces potential foreign exchange risks due to international sales and purchases, which could impact financial performance[148]. - The company is increasing R&D investments to address the risk of declining demand for human rabies vaccines in the long term[149]. Product Development and Innovation - The company is currently developing a new mRNA vaccine, expected to enter clinical trials by Q3 2022[26]. - The approval for clinical trials of the 15-valent HPV vaccine was received in December 2021, marking a significant breakthrough in innovative vaccine projects[53]. - The company is advancing the development of new technologies and processes for its existing vaccines, including the human rabies vaccine and the human Japanese encephalitis vaccine[66]. - The company’s innovative approaches in vaccine technology, such as the use of VLP technology, are expected to improve the safety and efficacy of its vaccine products[106]. Sales and Marketing - User data indicates that the company has expanded its customer base by 20% in the last year, reaching a total of 5 million active users[26]. - The company has a strong domestic sales team of nearly 300 professionals, covering all provinces and regions in China, and an international sales network in over 30 countries[128]. - The company is enhancing its marketing network and expanding its sales team to improve market penetration and brand recognition[139]. - The company has established strict management protocols for third-party promotional agencies and overseas distributors to mitigate risks[140]. Audit and Compliance - The company has received a standard unqualified audit opinion from Rongcheng Accounting Firm[7]. - The company has not reported any special arrangements for corporate governance[9].